Vanguard Group Inc. Has $175.96 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Vanguard Group Inc. raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 4.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,431,094 shares of the biopharmaceutical company's stock after buying an additional 390,116 shares during the quarter. Vanguard Group Inc. owned 7.07% of Catalyst Pharmaceuticals worth $175,957,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in shares of Catalyst Pharmaceuticals by 9.1% in the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company's stock valued at $8,116,000 after acquiring an additional 33,888 shares during the period. Farther Finance Advisors LLC boosted its holdings in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after purchasing an additional 1,495 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Catalyst Pharmaceuticals by 13.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock valued at $8,710,000 after purchasing an additional 50,888 shares during the period. Wellington Management Group LLP acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter worth $1,185,000. Finally, Redhawk Wealth Advisors Inc. bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $1,273,000. 79.22% of the stock is owned by institutional investors.

Remove Ads

Catalyst Pharmaceuticals Stock Up 2.8 %

Catalyst Pharmaceuticals stock traded up $0.60 during mid-day trading on Friday, hitting $22.05. 1,108,745 shares of the company were exchanged, compared to its average volume of 1,142,484. The company has a market capitalization of $2.68 billion, a PE ratio of 18.69, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79. The business has a fifty day moving average of $22.63 and a 200 day moving average of $22.00. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.47 and a 1-year high of $26.16.

Insider Buying and Selling

In related news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now directly owns 68,873 shares in the company, valued at $1,521,404.57. This represents a 39.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

CPRX has been the subject of several research reports. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Robert W. Baird raised their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens restated an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, Bank of America reiterated a "buy" rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.